AAD 2024: Deuruxolitinib Demonstrates Continued Improvement in Scalp Hair Regrowth Up to 68 Weeks in Patients With Alopecia Areata
At 68 weeks, 62.6 percent of participants receiving deuruxolitinib achieved SALT scores ≤20
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.